$5.6B global glaucoma market in for a shake-up; BMS hep C med loses FDA breakthrough rights; Actavis sells off acne med to Mayne Pharma;

> The $5.6 billion global glaucoma market is about to get a shake-up, as young companies such as Aerie Pharmaceuticals ($AERI) look to grab share for their own products. Story

> Bristol-Myers Squibb ($BMY) said its hepatitis C treatment daclatasvir is losing its FDA breakthrough therapy designation for genotype 1 patients, soon after Merck ($MRK) lost the breakthrough tag on its rival hep C cocktail. Story

> As it prepares to take over Allergan ($AGN) and its broad dermatology portfolio, Actavis ($ACT) is selling the U.S. rights to its Doryx acne treatment to Mayne Pharma for $50 million. Release

> Luitpold Pharmaceuticals is coming under fire from the FDA's Office of Prescription Drug Promotion for a promotional video for its iron-deficiency treatment Injectafer. Regulators say the video overstates its case for the drug and does not spell out its risks. Article (reg. req.)

> Healthcare professionals are venting on social media about U.K. cost watchdog NICE's new draft guidelines for diabetes meds, questioning in particular the agency's recommendations for Novo Nordisk's ($NVO) NovoNorm/Prandin tablets. Story

> ALK and bioCSL are teaming up to market ALK's allergy products in Australia and New Zealand. More

> John Kearney, Amgen's ($AMGN) U.K. and Ireland general manager, is taking over as president of the Association of the British Pharmaceutical Industry. Story

> Shares of Achillion Pharmaceuticals ($ACHN) climbed more than 11% Monday morning after the company announced promising results from a midstage clinical study of its experimental hepatitis C treatment. Article

> Michael du Toit has jumped ship at Publicis Healthcare Communications, where he was group co-chair, for the president's job at digital media company Everyday Health. Article (reg. req.)

And Finally… Pharma companies such as Biogen Idec ($BIIB) are using Twitter's promoted video feature to market products through social media. Story

Suggested Articles

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.